ReviewVaccines2026
The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.
Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Comparative epidemiology and preparedness for African swine fever and porcine reproductive and respiratory syndrome in four major Asian swine industries.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a contagious viral disease that causes severe economic losses in the global swine industry. Since its introduction to Vietnam in 2019, ASFV has evolved rapidly, with genotype II strains dominating initially and recombinant I/II variants emerging by 2023. Live attenuated vaccines (LAVs) have been developed and commercialized in Vietnam, including ASFV-G-ΔI177L, ASFV-G-ΔI177L/ΔLVR, and ASFV-G-ΔMGF, which confer homologous immune protection. Despite this, LAVs face challenges related to genetic stability, impossible protection against emerging recombinant strains, potential reversion to virulence, viral shedding, and safety in pregnant sows. ASFV's ongoing evolution underscores the need for continuous genomic surveillance, evaluation of cross-protective efficacy, and implementation of biosecurity and DIVA strategies focused more on evaluating vaccine efficacy than safety. This review summarizes the current molecular epidemiology of ASFV in Vietnam after vaccines were licensed for use, the development and performance of commercial LAVs, and the practical challenges of their application in endemic settings, and provides insights for informed vaccine deployment and integrated ASF control strategies in rapidly evolving viral landscapes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.